Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitogen-activated protein kinase kinase 6 antisense RNA 1 (MAP2K6-AS1)
- Target
- MAP2K6-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), antisense RNA
01
Overview
Mitogen-activated protein kinase kinase 6 antisense RNA 1 (MAP2K6-AS1, also called MEK6-AS1) is a long non-coding RNA highly expressed in human adipose and breast tissues. It is transcribed antisense to intron 1 of the MAP2K6 gene and plays a regulatory role in adipogenesis and fatty acid metabolism. MAP2K6-AS1 increases mRNA stability of MAP2K6 via interaction with NAT10, an RNA-binding acetyltransferase, and enhances adipogenic differentiation in mesenchymal stem cells. Its expression influences both pro-inflammatory and metabolic pathways but it is not considered a classical therapeutic target (enzyme, receptor, transporter)
- Other names
- MEK6-AS1
02
Mechanism of action
No drugs target MAP2K6-AS1 directly; mechanisms are regulatory (modulation of mRNA stability, cis-regulation of nearby genes, interaction with RNA-binding proteins like NAT10)
03
Biological functions
Regulation of mRNA stability (for MAP2K6)Regulation of adipogenic differentiation (modulates cell differentiation to adipocytes)Modulation of inflammatory cytokine secretionPost-transcriptional regulationFatty acid metabolism
04
Disease associations
Obesity (implicated in adipogenic differentiation)Metabolic disorders (via fatty acid metabolism)Potential role in cancer (by analogy to MAP2K6, but not directly established for MAP2K6-AS1)
05
Safety considerations
None documented; functional role in adipogenesis and cytokine regulation suggests relevance to metabolism and inflammation but no safety issues are reported
06
Interacting drugs
Adezmapimod
07
Biomarkers
adipogenic potentialmetabolic activity
Beyond the preview
Go deeper on Mitogen-activated protein kinase kinase 6 antisense RNA 1 (MAP2K6-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mitogen-activated protein kinase kinase 6 antisense RNA 1 (MAP2K6-AS1).